Search 

Theravance, Inc. - Medicines that Make A Difference®

Summary Products / Services / Technologies

Collaborations and Clients

About Threshold Pharmaceuticals
Threshold is a biotechnology company focused on the discovery and development of drugs targeting Tumor Hypoxia, the low oxygen condition found in microenvironments of most solid tumors as well as the bone marrows of some hematologic malignancies. This approach offers broad potential to treat a variety of cancers. By selectively targeting tumor cells, we are building a pipeline of drugs that hold promise to be more effective and less toxic to healthy tissues than conventional anticancer drugs. TH-302 is the lead and only clinical stage product in our pipeline.  For additional information, please visit our website (www.thresholdpharm.com).

About TH-302
TH-302 is a hypoxia-targeted drug that is thought to be activated under tumor hypoxic conditions, a hallmark of many cancer indications. Areas of low oxygen levels (hypoxia) within tissues are common in many solid tumors due to insufficient blood vessel growth.

TH-302 has been investigated in over 600 patients in Phase 1/2 clinical trials to date in a broad spectrum of tumor types, both as a monotherapy and in combination with chemotherapy treatments and other targeted cancer drugs. Threshold has several additional ongoing clinical trials, the most advanced of which is a Phase 3 pivotal study evaluating TH-302 in combination with doxorubicin versus doxorubicin alone in patients with soft tissue sarcoma. More recently, Threshold completed a 215 patient randomized Phase 2 in combination with gemcitabine vs gemcitabine alone in advanced pancreatic cancer.  The initial results we presented at AACR earlier this year and a follow up will be presented at ESMO in late September.

In February 2012, Threshold signed a global agreement with Merck KGaA, Darmstadt, Germany, to co-develop and co-commercialize TH-302.

Clinical stage biotech with a solution for gene/protein delviery to cancer cells.

Tocagen is a private biopharma developing a unique retroviral replicating vector (RRV) platform that can efficiently delivery a gene or protein of choice selectively to cancer cells.

·         A fundamental challenge in oncology is to selectively deliver active agents to cancer cells while sparing healthy tissue.  We believe we may have found a solution.
·         Unlike oncolytic viruses, RRVs are unique because they replicate by budding-off from the host cancer cell which allows "stealth" spread through cancer tissue without being cleared by the immune system.
·         Our RRV system is capable of delivering genes such as those that code for prodrug activator enzymes, shRNA, or therapeutic proteins.
·         Our lead RRV product candidate, Toca 511, delivers a prodrug activator gene, cytosine deaminase (CD), selectively to cancer cells.
·         Toca 511 is used in combination with Toca FC, a proprietary formulation of 5-FC, that is converted in the presence of CD in infected cancer cells to 5-FU.
·         To date, Toca 511 & 5-FC has been dosed in 36 patients with high grade glioma in two ascending dose Phase I trials.
·         In addition to a promising safety and efficacy profile in patients, we have also accumulated data in patients supporting the anticipated mechanism of action for this approach
·         Now that we have clinical validation for our technology platform, we are interested in partnership discussions e.g. building new RRV constructs for the delivery of a gene or protein of interest to the partner.

More details about our technology can be found at www.tocagen.com and more information about our clinical trials can be found here: http://clinicaltrials.gov/ct2/results?term=tocagen

Tranzyme Pharma is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing novel, mechanism-based therapeutics for the treatment of upper gastrointestinal (GI) motility disorders. While approximately 40 percent of people in the U.S. are affected by these persistent and recurring conditions which disrupt the normal movement of food throughout the GI tract, there are a limited number of safe and effective treatment options. Tranzyme is developing TZP-102, an oral ghrelin agonist for treating the symptoms associated with chronic upper GI motility disorders. Enrollment is complete in a multinational Phase 2b trial evaluating TZP-102 given once daily in diabetic patients with gastroparesis; top-line data are expected by year-end 2012. Tranzyme has initiated a second Phase 2b trial (DIGEST) evaluating TZP-102 given prior to meals in diabetic patients with gastroparesis; top-line data are expected in the first half of 2013. By leveraging its proprietary drug discovery technology, MATCH™, Tranzyme is committed to pursuing first-in-class medicines to address areas of significant unmet medical needs.

Trius Therapeutics is a biopharmaceutical company focused on the discovery, development and commercialization of innovative antibiotics for life-threatening infections.

We have successfully completed our first Phase 3 clinical trial for Tedizolid Phosphate (TR-701), formerly torezolid phosphate, in ABSSSI. Tedizolid is an IV and orally administered second generation oxazolidinone, for the treatment of serious gram-positive bacterial infections, including those caused by methicillin-resistant Staphylococcus aureus (MRSA). With the continuous increase in bacterial resistance to currently marketed drugs, serious infections are becoming more difficult, if not impossible to treat, and this has led to a clear need for novel therapeutics to treat multi-drug resistant bacterial infections.

 Trius is headquartered in San Diego, California. 

Upsher-Smith Laboratories, Inc. is pursuing improved drug therapies to improve people’s lives.  The evolution of their company is driven by the ever-changing needs of patients, physicians, pharmacists, and healthcare organizations.  Their perspective is not “more products,” but the right products that make people’s lives better.  At every level of their business, they are driven to be the best.

Upsher-Smith is actively pursuing product development opportunities in the therapeutic areas of epilepsy and Parkinson’s disease; their current product portfolio is focused in the areas of women’s health, dermatology, and cardiology.   

With a track record of successful collaboration in licensing and acquiring innovative products, Upsher-Smith is a trusted partner to many leading pharmaceutical companies, offering expertise in:   

• Conducting clinical trials to support safety and efficacy
• Preparing and managing submissions for the FDA review process
• Commercialization and distribution of products to the retail and wholesale trade
• Marketing and sales promotions through sales force, national conventions, professional advertising, and other media 

As an independent and privately held company, Upsher-Smith acts swiftly to create the right partnerships and connections that build upon their success.

On August 14, 2012, the company completed its acquisition of UK-based Proximagen Group plc, a European biotechnology company focused on the development and commercialization of novel therapeutics for diseases of the central nervous system and inflammation. 

Upsher-Smith also has offices in Plymouth, MN, Denver, CO and Morristown, NJ.

“Advancing pharmacotherapy.  Improving lifeSM”….  As the company evolves, Upsher-Smith’s goal remains the same:  to assist individuals in making the best use of medicines.  This not only means producing quality pharmaceutical products, but providing access to them as well.  The company promises to provide reliable, affordable products that have a daily impact to improve lives.

Upsher-Smith’s vision is to become a leader in providing therapies that empower people suffering from central nervous system (CNS) diseases to lead healthy, productive lives.

We are a specialty pharmaceutical company intent on utilizing our proven business model of creating value through accretive product acquisitions or license agreements, sound marketing and distribution, and life cycle management.

In June 2012 we acquired Actimmune (Interferon Gamma) our first product acquisition.  Actimmune is indicated for reducing the frequency and severity of serious infections associated with Chronic Granulomatous Disease and delaying time to disease progression in patients with Severe, Malignant Osteopetrosis.  

We are seeking to acquire both commercial and late stage specialty niche therapeutics.  

Vidara is a fully financed and profitable specialty pharmaceutical company.  

Viscadia is an analytically-driven management consulting firm that partners with companies in specialty pharmaceutical markets. Viscadia identifies and evaluates development, acquisition, licensing and life-cycle management opportunities. Additionally, Viscadia analyzes and optimizes the execution of specialty pharmaceutical commercial strategies. Viscadia is headquartered in San Diego, CA with a regional office in St. Louis, MO. For more information about Viscadia, email info@viscadia.com, call +1 858 496 7500 or visit www.viscadia.com.